Harry Bartelink

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Concepts & Ideas

Procedures

Chemicals & Drugs

Living Beings

Inbred C3H Mice

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Jones Heather A; Antonini Ninja; Hart Augustinus A M; Peterse Johannes L; Horiot Jean-Claude; Collin Françoise; Poortmans Philip M; Oei S Bing; Collette Laurence; Struikmans Henk; Van den Bogaert Walter F; Fourquet Alain; Jager Jos J; Schinagl Dominic A X; Wárlám-Rodenhuis Carla C; Bartelink Harry
Impact of pathological characteristics on local relapse after breast-conserving therapy: a subgroup analysis of the EORTC boost versus no boost trial.
Stroom Joep; Schlief Angelique; Alderliesten Tanja; Peterse Hans; Bartelink Harry; Gilhuijs Kenneth
Using histopathology breast cancer data to reduce clinical target volume margins at radiotherapy.
Pengel K E; Loo C E; Teertstra H J; Muller S H; Wesseling J; Peterse J L; Bartelink H; Rutgers E J; Gilhuijs K G A
The impact of preoperative MRI on breast-conserving surgery of invasive cancer: a comparative cohort study.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Harry Bartelink (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Jones Heather A; Antonini Ninja; Hart Augustinus A M; Peterse Johannes L; Horiot Jean-Claude; Collin Françoise; Poortmans Philip M; Oei S Bing; Collette Laurence; Struikmans Henk; Van den Bogaert Walter F; Fourquet Alain; Jager Jos J; Schinagl Dominic A X; Wárlám-Rodenhuis Carla C; Bartelink Harry
Impact of pathological characteristics on local relapse after breast-conserving therapy: a subgroup analysis of the EORTC boost versus no boost trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(30):4939-47.
2009: Stroom Joep; Schlief Angelique; Alderliesten Tanja; Peterse Hans; Bartelink Harry; Gilhuijs Kenneth
Using histopathology breast cancer data to reduce clinical target volume margins at radiotherapy.
International journal of radiation oncology, biology, physics 2009;74(3):898-905.
2009: Pengel K E; Loo C E; Teertstra H J; Muller S H; Wesseling J; Peterse J L; Bartelink H; Rutgers E J; Gilhuijs K G A
The impact of preoperative MRI on breast-conserving surgery of invasive cancer: a comparative cohort study.
Breast cancer research and treatment 2009;116(1):161-9.
2009: Kreike Bas; Halfwerk Hans; Armstrong Nicola; Bult Peter; Foekens John A; Veltkamp Sanne C; Nuyten Dimitry S A; Bartelink Harry; van de Vijver Marc J
Local recurrence after breast-conserving therapy in relation to gene expression patterns in a large series of patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(12):4181-90.
2009: Zerp Shuraila F; Stoter Rianne; Kuipers Gitta; Yang Dajun; Lippman Marc E; van Blitterswijk Wim J; Bartelink Harry; Rooswinkel Rogier; Lafleur Vincent; Verheij Marcel
AT-101, a small molecule inhibitor of anti-apoptotic Bcl-2 family members, activates the SAPK/JNK pathway and enhances radiation-induced apoptosis.
Radiation oncology (London, England) 2009;4():47.
2008: Collette Sandra; Collette Laurence; Budiharto Tom; Horiot Jean-Claude; Poortmans Philip M; Struikmans Henk; Van den Bogaert Walter; Fourquet Alain; Jager Jos J; Hoogenraad Willem; Mueller Rolf-Peter; Kurtz John; Morgan David A L; Dubois Jean-Bernard; Salamon Emile; Mirimanoff Rene; Bolla Michel; Van der Hulst Marleen; Wárlám-Rodenhuis Carla C; Bartelink Harry;
Predictors of the risk of fibrosis at 10 years after breast conserving therapy for early breast cancer: a study based on the EORTC Trial 22881-10882 'boost versus no boost'.
European journal of cancer (Oxford, England : 1990) 2008;44(17):2587-99.
2008: Kreike Bas; Hart Augustinus A M; van de Velde Tony; Borger Jacques; Peterse Hans; Rutgers Emiel; Bartelink Harry; van de Vijver Marc J
Continuing risk of ipsilateral breast relapse after breast-conserving therapy at long-term follow-up.
International journal of radiation oncology, biology, physics 2008;71(4):1014-21.
2008: Hoebers F J P; Pluim D; Hart A A M; Verheij M; Balm A J M; Fons G; Rasch C R N; Schellens J H M; Stalpers L J A; Bartelink H; Begg A C
Cisplatin-DNA adduct formation in patients treated with cisplatin-based chemoradiation: lack of correlation between normal tissues and primary tumor.
Cancer chemotherapy and pharmacology 2008;61(6):1075-81.
2008: Bartelink Harry; Begg Adrian C
Prognostic and predictive markers in oncology. Introduction.
Seminars in radiation oncology 2008;18(2):73-4.
2008: Bartelink Harry; Arriagada Rodrigo
Hypofractionation in radiotherapy for breast cancer.
Lancet 2008;371(9618):1050-2.
2008: Zerp Shuraila F; Vink Stefan R; Ruiter Gerald A; Koolwijk Pieter; Peters Erna; van der Luit Arnold H; de Jong Daphne; Budde Marianne; Bartelink Harry; van Blitterswijk Wim J; Verheij Marcel
Alkylphospholipids inhibit capillary-like endothelial tube formation in vitro: antiangiogenic properties of a new class of antitumor agents.
Anti-cancer drugs 2008;19(1):65-75.
2008: Meijnen Philip; Oldenburg Hester S A; Peterse Johannes L; Bartelink Harry; Rutgers Emiel J Th
Clinical outcome after selective treatment of patients diagnosed with ductal carcinoma in situ of the breast.
Annals of surgical oncology 2008;15(1):235-43.
2007: Meijnen Philip; Bartelink Harry
Multifocal ductal carcinoma in situ of the breast: a contraindication for breast-conserving treatment?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(35):5548-9.
2007: Jansen Edwin P M; Boot Henk; Saunders Mark P; Crosby Tom D L; Dubbelman Ria; Bartelink Harry; Verheij Marcel; Cats Annemieke
A phase I-II study of postoperative capecitabine-based chemoradiotherapy in gastric cancer.
International journal of radiation oncology, biology, physics 2007;69(5):1424-8.
2007: Jansen E P M; Boot H; Dubbelman R; Bartelink H; Cats A; Verheij M
Postoperative chemoradiotherapy in gastric cancer -- a Phase I/II dose-finding study of radiotherapy with dose escalation of cisplatin and capecitabine chemotherapy.
British journal of cancer 2007;97(6):712-6.
2007: Bartelink Harry; Horiot Jean-Claude; Poortmans Philip M; Struikmans Henk; Van den Bogaert Walter; Fourquet Alain; Jager Jos J; Hoogenraad Willem J; Oei S Bing; Wárlám-Rodenhuis Carla C; Pierart Marianne; Collette Laurence
Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(22):3259-65.
2007: Hooning Maartje J; Botma Akke; Aleman Berthe M P; Baaijens Margreet H A; Bartelink Harry; Klijn Jan G M; Taylor Carolyn W; van Leeuwen Flora E
Long-term risk of cardiovascular disease in 10-year survivors of breast cancer.
Journal of the National Cancer Institute 2007;99(5):365-75.
2007: Musat Elena; Poortmans Philip; Van den Bogaert Walter; Struikmans Henk; Fourquet Alain; Bartelink Harry; Kirkove Carine; Budach Volker; Pierart Marianne; Collette Laurence
Quality assurance in breast cancer: EORTC experiences in the phase III trial on irradiation of the internal mammary nodes.
European journal of cancer (Oxford, England : 1990) 2007;43(4):718-24.
2007: Jansen Edwin P M; Saunders Mark P; Boot Henk; Oppedijk Vera; Dubbelman Ria; Porritt Bridget; Cats Annemieke; Stroom Joep; Valdés Olmos Renato; Bartelink Harry; Verheij Marcel
Prospective study on late renal toxicity following postoperative chemoradiotherapy in gastric cancer.
International journal of radiation oncology, biology, physics 2007;67(3):781-5.
2007: Antonini Ninja; Jones Heather; Horiot Jean Claude; Poortmans Philip; Struikmans Henk; Van den Bogaert Walter; Barillot Isabelle; Fourquet Alain; Jager Jos; Hoogenraad Willem; Collette Laurence; Pierart Marianne; Hart Guus; Bartelink Harry
Effect of age and radiation dose on local control after breast conserving treatment: EORTC trial 22881-10882.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2007;82(3):265-71.
2007: Aleman Berthe M P; van den Belt-Dusebout Alexandra W; De Bruin Marie L; van 't Veer Mars B; Baaijens Margreet H A; de Boer Jan Paul; Hart Augustinus A M; Klokman Willem J; Kuenen Marianne A; Ouwens Gabey M; Bartelink Harry; van Leeuwen Flora E
Late cardiotoxicity after treatment for Hodgkin lymphoma.
Blood 2007;109(5):1878-86.
2007: Belderbos José; Uitterhoeve Lon; van Zandwijk Nico; Belderbos Huub; Rodrigus Patrick; van de Vaart Paul; Price Allan; van Walree Nico; Legrand Catherine; Dussenne Sonia; Bartelink Harry; Giaccone Giuseppe; Koning Caro;
Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973).
European journal of cancer (Oxford, England : 1990) 2007;43(1):114-21.
2007: Kreike Bas; van Kouwenhove Marieke; Horlings Hugo; Weigelt Britta; Peterse Hans; Bartelink Harry; van de Vijver Marc J
Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas.
Breast cancer research : BCR 2007;9(5):R65.
2006: Kreike Bas; Halfwerk Hans; Kristel Petra; Glas Annuska; Peterse Hans; Bartelink Harry; van de Vijver Marc J
Gene expression profiles of primary breast carcinomas from patients at high risk for local recurrence after breast-conserving therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(19):5705-12.
2006: Vink Stefan R; Schellens Jan H M; Beijnen Jos H; Sindermann Herbert; Engel Jürgen; Dubbelman Ria; Moppi Gemi; Hillebrand Michel J X; Bartelink Harry; Verheij Marcel
Phase I and pharmacokinetic study of combined treatment with perifosine and radiation in patients with advanced solid tumours.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2006;80(2):207-13.
2006: Hoebers Frank J P; Pluim Dick; Verheij Marcel; Balm Alfons J M; Bartelink Harry; Schellens Jan H M; Begg Adrian C
Prediction of treatment outcome by cisplatin-DNA adduct formation in patients with stage III/IV head and neck squamous cell carcinoma, treated by concurrent cisplatin-radiation (RADPLAT).
International journal of cancer. Journal international du cancer 2006;119(4):750-6.
2006: Bijker Nina; Meijnen Philip; Peterse Johannes L; Bogaerts Jan; Van Hoorebeeck Irène; Julien Jean-Pierre; Gennaro Massimiliano; Rouanet Philippe; Avril Antoine; Fentiman Ian S; Bartelink Harry; Rutgers Emiel J Th
Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853--a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(21):3381-7.
2006: Deurloo Eline E; Klein Zeggelink William F A; Teertstra H Jelle; Peterse Johannes L; Rutgers Emiel J Th; Muller Sara H; Bartelink Harry; Gilhuijs Kenneth G A
Contrast-enhanced MRI in breast cancer patients eligible for breast-conserving therapy: complementary value for subgroups of patients.
European radiology 2006;16(3):692-701.
2006: Nuyten Dimitry S A; Kreike Bas; Hart Augustinus A M; Chi Jen-Tsan Ashley; Sneddon Julie B; Wessels Lodewyk F A; Peterse Hans J; Bartelink Harry; Brown Patrick O; Chang Howard Y; van de Vijver Marc J
Predicting a local recurrence after breast-conserving therapy by gene expression profiling.
Breast cancer research : BCR 2006;8(5):R62.
2005: Poortmans Philip M P; Ataman Fatma; Davis Jacques Bernard; Bartelink Harry; Horiot Jean-Claude; Pierart Marianne; Collette Laurence; Van Tienhoven Geertjan
Quality assurance in the EORTC phase III randomised 'boost vs. no boost' trial for breast conserving therapy: comparison of the results of two individual case reviews performed early and late during the accrual period.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2005;76(3):278-84.
2005: Haas R L M; Poortmans Ph; de Jong D; Verheij M; van der Hulst M; de Boer J P; Bartelink H
Effective palliation by low dose local radiotherapy for recurrent and/or chemotherapy refractory non-follicular lymphoma patients.
European journal of cancer (Oxford, England : 1990) 2005;41(12):1724-30.
2005: Dorresteijn L D A; Marres H A M; Bartelink H; Kappelle L J; Boogerd W; Kappelle A C
[Radiotherapy of the neck as a risk factor for stroke]
Nederlands tijdschrift voor geneeskunde 2005;149(23):1249-53.
2005: Dorresteijn Lucille D A; Kappelle Arnoud C; Scholz Natasja M J; Munneke Marten; Scholma José T; Balm Alfons J M; Bartelink Harry; Boogerd Willem
Increased carotid wall thickening after radiotherapy on the neck.
European journal of cancer (Oxford, England : 1990) 2005;41(7):1026-30.
2005: Pos Floris; Horenblas Simon; Dom Paul; Moonen Luc; Bartelink Harry
Organ preservation in invasive bladder cancer: brachytherapy, an alternative to cystectomy and combined modality treatment?
International journal of radiation oncology, biology, physics 2005;61(3):678-86.
2005: Chang Howard Y; Nuyten Dimitry S A; Sneddon Julie B; Hastie Trevor; Tibshirani Robert; Sørlie Therese; Dai Hongyue; He Yudong D; van't Veer Laura J; Bartelink Harry; van de Rijn Matt; Brown Patrick O; van de Vijver Marc J
Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival.
Proceedings of the National Academy of Sciences of the United States of America 2005;102(10):3738-43.
2004: Russell Nicola S; Bartelink Harry
Sophisticated radiotherapy with optimal surgery is the way forward.
Current opinion in oncology 2004;16(6):529-35.
2004: Poortmans Philip; Bartelink Harry; Horiot Jean-Claude; Struikmans Henk; Van den Bogaert Walter; Fourquet Alain; Jager Jos; Hoogenraad Willem; Rodrigus Patrick; Wárlám-Rodenhuis Carla; Collette Laurence; Pierart Marianne;
The influence of the boost technique on local control in breast conserving treatment in the EORTC 'boost versus no boost' randomised trial.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2004;72(1):25-33.
2004: Haas Rick L M; de Jong Daphne; Valdés Olmos Renato A; Hoefnagel Cees A; van den Heuvel Iris; Zerp Shuraila F; Bartelink Harry; Verheij Marcel
In vivo imaging of radiation-induced apoptosis in follicular lymphoma patients.
International journal of radiation oncology, biology, physics 2004;59(3):782-7.
2004: Pos Floris J; Horenblas Simon; Lebesque Joos; Moonen Luc; Schneider Christoph; Sminia Peter; Bartelink Harry
Low-dose-rate brachytherapy is superior to high-dose-rate brachytherapy for bladder cancer.
International journal of radiation oncology, biology, physics 2004;59(3):696-705.
2004: Artignan Xavier; Smitsmans Monique H P; Lebesque Jos V; Jaffray David A; van Her Marcel; Bartelink Harry
Online ultrasound image guidance for radiotherapy of prostate cancer: impact of image acquisition on prostate displacement.
International journal of radiation oncology, biology, physics 2004;59(2):595-601.
2004: Bartelink Harry
Intraoperative radiotherapy for breast cancer: tail wagging the dog?
The lancet oncology 2004;5(4):207-8.
2004: Cho B C John; Schwarz Marco; Mijnheer Ben J; Bartelink Harry
Simplified intensity-modulated radiotherapy using pre-defined segments to reduce cardiac complications in left-sided breast cancer.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2004;70(3):231-41.
2004: Aleman Berthe M P; Russell Nicola S; Bartelink Harry; van Leeuwen Flora E
Re: Radiation therapy in the treatment of Hodgkin's disease--do you see what I see?
Journal of the National Cancer Institute 2004;96(3):235-6; author reply 236-7.
2004: Cho B C John; Mijnheer Ben J; Bartelink Harry
Determining optimal two-beam axial orientations for heart sparing in left-sided breast cancer patients.
Medical physics 2004;31(1):111-21.
2004: Nieweg O E; Bartelink H
Implications of lymphatic mapping for staging and adjuvant treatment of patients with breast cancer.
European journal of cancer (Oxford, England : 1990) 2004;40(2):179-81.
2003: Bartelink Harry
Radiotherapy to the conserved breast, chest wall, and regional nodes: is there a standard?
Breast (Edinburgh, Scotland) 2003;12(6):475-82.
2003: Haas Rick L M; Valdés-Olmos Renato A; Hoefnagel Cornelis A; Verheij Marcel; de Jong Daphne; Hart Augustinus A M; Bartelink Harry
Thallium-201-chloride scintigraphy in staging and monitoring radiotherapy response in follicular lymphoma patients.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2003;69(3):323-8.
2003: Zeggelink William F A Klein; Deurloo Eline E; Bartelink Harry; Rutgers Emiel J Th; Gilhuijs Kenneth G A
Reproducibility of the assessment of tumor extent in the breast using multiple image modalities.
Medical physics 2003;30(11):2919-26.
2003: Aleman Berthe M P; van den Belt-Dusebout Alexandra W; Klokman Willem J; Van't Veer Mars B; Bartelink Harry; van Leeuwen Flora E
Long-term cause-specific mortality of patients treated for Hodgkin's disease.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(18):3431-9.
2003: Bartelink Harry; Benz Christopher; Cleveland Don; Dorn Ronald; Gralow Julie; Gradishar William J; Grant Kathleen; Heimann Ruth; Hellman Samuel; Hudis Clifford; Kerbel Robert; Lippman Marc; Lung John; Posner Mitchell C; Steeg Patricia; Vestal Robert; Weichselbaum Ralph R; Zetter Bruce
Expedition Inspiration Fund for Breast Cancer Research Meeting 2003.
Breast cancer research and treatment 2003;80(2):139-44.
2003: Haas R L M; Poortmans Ph; de Jong D; Aleman B M P; Dewit L G H; Verheij M; Hart A A M; van Oers M H J; van der Hulst M; Baars J W; Bartelink H
High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(13):2474-80.
2003: Vrieling C; Collette L; Fourquet A; Hoogenraad W J; Horiot J-C; Jager J J; Bing Oei S; Peterse H L; Pierart M; Poortmans P M; Struikmans H; Van den Bogaert W; Bartelink H;
Can patient-, treatment- and pathology-related characteristics explain the high local recurrence rate following breast-conserving therapy in young patients?
European journal of cancer (Oxford, England : 1990) 2003;39(7):932-44.
2003: Ruiter Gerald A; Zerp Shuraila F; Bartelink Harry; van Blitterswijk Wim J; Verheij Marcel
Anti-cancer alkyl-lysophospholipids inhibit the phosphatidylinositol 3-kinase-Akt/PKB survival pathway.
Anti-cancer drugs 2003;14(2):167-73.
2002: van de Vijver Marc J; He Yudong D; van't Veer Laura J; Dai Hongyue; Hart Augustinus A M; Voskuil Dorien W; Schreiber George J; Peterse Johannes L; Roberts Chris; Marton Matthew J; Parrish Mark; Atsma Douwe; Witteveen Anke; Glas Annuska; Delahaye Leonie; van der Velde Tony; Bartelink Harry; Rodenhuis Sjoerd; Rutgers Emiel T; Friend Stephen H; Bernards René
A gene-expression signature as a predictor of survival in breast cancer.
The New England journal of medicine 2002;347(25):1999-2009.
2002: Cho B C John; van Herk Marcel; Mijnheer Ben J; Bartelink Harry
The effect of set-up uncertainties, contour changes, and tissue inhomogeneities on target dose-volume histograms.
Medical physics 2002;29(10):2305-18.
2002: Vens Conchita; Dahmen-Mooren Els; Verwijs-Janssen Manon; Blyweert Wim; Graversen Lise; Bartelink Harry; Begg Adrian C
The role of DNA polymerase beta in determining sensitivity to ionizing radiation in human tumor cells.
Nucleic acids research 2002;30(13):2995-3004.
2002: Bartelink H; Van den Bogaert W; Horiot J-C; Jager J; van Glabbeke M
Concomitant cisplatin and radiotherapy in a conventional and modified fractionation schedule in locally advanced head and neck cancer: a randomised phase II EORTC trial.
European journal of cancer (Oxford, England : 1990) 2002;38(5):667-73.
2002: Bartelink H; Schellens J H M; Verheij M
The combined use of radiotherapy and chemotherapy in the treatment of solid tumours.
European journal of cancer (Oxford, England : 1990) 2002;38(2):216-22.
2002: Dorresteijn Lucille D A; Kappelle Arnoud C; Boogerd Willem; Klokman Willem J; Balm Alfons J M; Keus Ronald B; van Leeuwen Flora E; Bartelink Harry
Increased risk of ischemic stroke after radiotherapy on the neck in patients younger than 60 years.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(1):282-8.
2001: Bartelink H; Horiot J C; Poortmans P; Struikmans H; Van den Bogaert W; Barillot I; Fourquet A; Borger J; Jager J; Hoogenraad W; Collette L; Pierart M;
Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation.
The New England journal of medicine 2001;345(19):1378-87.
2001: Ong F; Moonen L M; Gallee M P; ten Bosch C; Zerp S F; Hart A A; Bartelink H; Verheij M
Prognostic factors in transitional cell cancer of the bladder: an emerging role for Bcl-2 and p53.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2001;61(2):169-75.
2001: Bosset J F; Horiot J C; Hamers H P; Cionini L; Bartelink H; Caspers R; Untereiner M; Ciambelloti E; Pierart M; Van Glabbeke M
Postoperative pelvic radiotherapy with or without elective irradiation of para-aortic nodes and liver in rectal cancer patients. A controlled clinical trial of the EORTC Radiotherapy Group.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2001;61(1):7-13.
2001: Moonen L; Ong F; Gallee M; Verheij M; Horenblas S; Hart A A; Bartelink H
Apoptosis, proliferation and p53, cyclin D1, and retinoblastoma gene expression in relation to radiation response in transitional cell carcinoma of the bladder.
International journal of radiation oncology, biology, physics 2001;49(5):1305-10.
2001: Voogd A C; Nielsen M; Peterse J L; Blichert-Toft M; Bartelink H; Overgaard M; van Tienhoven G; Andersen K W; Sylvester R J; van Dongen J A;
Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(6):1688-97.
2001: Bartelink H
From translational research to improved local control and survival: the Gilbert Fletcher Award Lecture, Lugano, March 2000.
International journal of radiation oncology, biology, physics 2001;49(2):311-8.
2001: Schornagel J H; Verheij M; Bartelink H
Concurrent chemotherapy and radiation for locally advanced squamous cell cancers: what is the schedule of choice?
Current oncology reports 2001;3(1):1-2.
2000: Jansen E P; Dewit L G; van Herk M; Bartelink H
Target volumes in radiotherapy for high-grade malignant glioma of the brain.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2000;56(2):151-6.
2000: Jansen E P; Keus R B; Hilgers F J; Haas R L; Tan I B; Bartelink H
Does the combination of radiotherapy and debulking surgery favor survival in paranasal sinus carcinoma?
International journal of radiation oncology, biology, physics 2000;48(1):27-35.
2000: van Dongen J A; Voogd A C; Fentiman I S; Legrand C; Sylvester R J; Tong D; van der Schueren E; Helle P A; van Zijl K; Bartelink H
Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial.
Journal of the National Cancer Institute 2000;92(14):1143-50.
2000: Vrieling C; Collette L; Fourquet A; Hoogenraad W J; Horiot J H; Jager J J; Pierart M; Poortmans P M; Struikmans H; Maat B; Van Limbergen E; Bartelink H
The influence of patient, tumor and treatment factors on the cosmetic results after breast-conserving therapy in the EORTC 'boost vs. no boost' trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2000;55(3):219-32.
2000: van de Vaart P J; Belderbos J; de Jong D; Sneeuw K C; Majoor D; Bartelink H; Begg A C
DNA-adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy.
International journal of cancer. Journal international du cancer 2000;89(2):160-6.
2000: Uitterhoeve A L; Belderbos J S; Koolen M G; van der Vaart P J; Rodrigus P T; Benraadt J; Koning C C; González González D; Bartelink H
Toxicity of high-dose radiotherapy combined with daily cisplatin in non-small cell lung cancer: results of the EORTC 08912 phase I/II study. European Organization for Research and Treatment of Cancer.
European journal of cancer (Oxford, England : 1990) 2000;36(5):592-600.
2000: Russell N S; Lara P C; Grummels A; Hart A A; Coco-Martin J M; Bartelink H; Begg A C
In vitro differentiation characteristics of human skin fibroblasts: correlations with radiotherapy-induced breast fibrosis in patients.
International journal of radiation biology 2000;76(2):231-40.
2000: Julien J P; Bijker N; Fentiman I S; Peterse J L; Delledonne V; Rouanet P; Avril A; Sylvester R; Mignolet F; Bartelink H; Van Dongen J A
Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853. EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group.
Lancet 2000;355(9203):528-33.
2000: Bartelink H; Begg A C; Martin J C; van Dijk M; Moonen L; van 't Veer L J; Van de Vaart P; Verheij M
Translational research offers individually tailored treatments for cancer patients.
The cancer journal from Scientific American 2000;6(1):2-10.
1999: Russell N S; Bartelink H
Radiotherapy: the last 25 years.
Cancer treatment reviews 1999;25(6):365-76.
1999: Vrieling C; Collette L; Fourquet A; Hoogenraad W J; Horiot J C; Jager J J; Pierart M; Poortmans P M; Struikmans H; Van der Hulst M; Van der Schueren E; Bartelink H
The influence of the boost in breast-conserving therapy on cosmetic outcome in the EORTC "boost versus no boost" trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups. European Organization for Research and Treatment of Cancer.
International journal of radiation oncology, biology, physics 1999;45(3):677-85.
1999: Vrieling C; Collette L; Bartelink E; Borger J H; Brenninkmeyer S J; Horiot J C; Pierart M; Poortmans P M; Struikmans H; Van der Schueren E; Van Dongen J A; Van Limbergen E; Bartelink H
Validation of the methods of cosmetic assessment after breast-conserving therapy in the EORTC "boost versus no boost" trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups. European Organization for Research and Treatment of Cancer.
International journal of radiation oncology, biology, physics 1999;45(3):667-76.
1999: Coco Martin J M; Mooren E; Ottenheim C; Burrill W; Nunez M I; Sprong D; Bartelink H; Begg A C
Potential of radiation-induced chromosome aberrations to predict radiosensitivity in human tumour cells.
International journal of radiation biology 1999;75(9):1161-8.
1999: Bartelink H
Is neoadjuvant chemotherapy the answer for bladder cancer?
Lancet 1999;354(9178):526-7.
1999: Verdonck-de Leeuw I M; Keus R B; Hilgers F J; Koopmans-van Beinum F J; Greven A J; de Jong J M; Vreeburg G; Bartelink H
Consequences of voice impairment in daily life for patients following radiotherapy for early glottic cancer: voice quality, vocal function, and vocal performance.
International journal of radiation oncology, biology, physics 1999;44(5):1071-8.
1999: Ruiter G A; Zerp S F; Bartelink H; van Blitterswijk W J; Verheij M
Alkyl-lysophospholipids activate the SAPK/JNK pathway and enhance radiation-induced apoptosis.
Cancer research 1999;59(10):2457-63.
1999: Verdonck-de Leeuw I M; Hilgers F J; Keus R B; Koopmans-van Beinum F J; Greven A J; de Jong J M; Vreeburg G; Bartelink H
Multidimensional assessment of voice characteristics after radiotherapy for early glottic cancer.
The Laryngoscope 1999;109(2 Pt 1):241-8.
1999: Begg A C; Haustermans K; Hart A A; Dische S; Saunders M; Zackrisson B; Gustaffson H; Coucke P; Paschoud N; Hoyer M; Overgaard J; Antognoni P; Richetti A; Bourhis J; Bartelink H; Horiot J C; Corvo R; Giaretti W; Awwad H; Shouman T; Jouffroy T; Maciorowski Z; Dobrowsky W; Struikmans H; Wilson G D
The value of pretreatment cell kinetic parameters as predictors for radiotherapy outcome in head and neck cancer: a multicenter analysis.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 1999;50(1):13-23.
1999: Bartelink H; Begg A; Martin J C; van Dijk M; van 't Veer L; van der Vaart P; Verheij M
Towards prediction and modulation of treatment response.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 1999;50(1):1-11.
1999: van Tienhoven G; Voogd A C; Peterse J L; Nielsen M; Andersen K W; Mignolet F; Sylvester R; Fentiman I S; van der Schueren E; van Zijl K; Blichert-Toft M; Bartelink H; van Dongen J A
Prognosis after treatment for loco-regional recurrence after mastectomy or breast conserving therapy in two randomised trials (EORTC 10801 and DBCG-82TM). EORTC Breast Cancer Cooperative Group and the Danish Breast Cancer Cooperative Group.
European journal of cancer (Oxford, England : 1990) 1999;35(1):32-8.
1999: Ptaszynski A M; Van den Bogaert W; Horiot J C; Poortmans P; Fourquet A; Struikmans H; Bartelink H; Pierart M; Collette L; van der Schueren E
Radiation dose homogeneity in an EORTC multicenter trial on breast irradiation.
Acta oncologica (Stockholm, Sweden) 1999;38 Suppl 13():19-27.
1998: Moonen L; vd Voet H; de Nijs R; Hart A A; Horenblas S; Bartelink H
Muscle-invasive bladder cancer treated with external beam radiotherapy: pretreatment prognostic factors and the predictive value of cystoscopic re-evaluation during treatment.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 1998;49(2):149-55.
1998: Moonen L; vd Voet H; de Nijs R; Horenblas S; Hart A A; Bartelink H
Muscle-invasive bladder cancer treated with external beam radiation: influence of total dose, overall treatment time, and treatment interruption on local control.
International journal of radiation oncology, biology, physics 1998;42(3):525-30.
1998: van der Voet J C; Keus R B; Hart A A; Hilgers F J; Bartelink H
The impact of treatment time and smoking on local control and complications in T1 glottic cancer.
International journal of radiation oncology, biology, physics 1998;42(2):247-55.
1998: Russell N S; Grummels A; Hart A A; Smolders I J; Borger J; Bartelink H; Begg A C
Low predictive value of intrinsic fibroblast radiosensitivity for fibrosis development following radiotherapy for breast cancer.
International journal of radiation biology 1998;73(6):661-70.
1998: Verheij M; Ruiter G A; Zerp S F; van Blitterswijk W J; Fuks Z; Haimovitz-Friedman A; Bartelink H
The role of the stress-activated protein kinase (SAPK/JNK) signaling pathway in radiation-induced apoptosis.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 1998;47(3):225-32.
1998: Curran D; van Dongen J P; Aaronson N K; Kiebert G; Fentiman I S; Mignolet F; Bartelink H
Quality of life of early-stage breast cancer patients treated with radical mastectomy or breast-conserving procedures: results of EORTC Trial 10801. The European Organization for Research and Treatment of Cancer (EORTC), Breast Cancer Co-operative Group (BCCG).
European journal of cancer (Oxford, England : 1990) 1998;34(3):307-14.
1998: van de Vaart P J; van der Vange N; Zoetmulder F A; van Goethem A R; van Tellingen O; ten Bokkel Huinink W W; Beijnen J H; Bartelink H; Begg A C
Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines.
European journal of cancer (Oxford, England : 1990) 1998;34(1):148-54.
1998: Verheij M; van Blitterswijk W J; Bartelink H
Radiation-induced apoptosis--the ceramide-SAPK signaling pathway and clinical aspects.
Acta oncologica (Stockholm, Sweden) 1998;37(6):575-81.
1997: Rasch C; Keus R; Pameijer F A; Koops W; de Ru V; Muller S; Touw A; Bartelink H; van Herk M; Lebesque J V
The potential impact of CT-MRI matching on tumor volume delineation in advanced head and neck cancer.
International journal of radiation oncology, biology, physics 1997;39(4):841-8.
1997: Haas R L; Keus R B; Loftus B M; Rutgers E J; van Coevorden F; Bartelink H
The role of radiotherapy in the local management of dermatofibrosarcoma protuberans. Soft Tissue Tumours Working Group.
European journal of cancer (Oxford, England : 1990) 1997;33(7):1055-60.
1997: Bartelink H; Roelofsen F; Eschwege F; Rougier P; Bosset J F; Gonzalez D G; Peiffert D; van Glabbeke M; Pierart M
Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(5):2040-9.
1997: Moonen L; van der Voet H; Horenblas S; Bartelink H
A feasibility study of accelerated fractionation in radiotherapy of carcinoma of the urinary bladder.
International journal of radiation oncology, biology, physics 1997;37(3):537-42.
1997: Pignon T; Horiot J C; Bolla M; van Poppel H; Bartelink H; Roelofsen F; Pene F; Gerard A; Einhorn N; Nguyen T D; Vanglabbeke M; Scalliet P
Age is not a limiting factor for radical radiotherapy in pelvic malignancies.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 1997;42(2):107-20.
1997: Bosset J F; Pavy J J; Roelofsen F; Bartelink H
Combined radiotherapy and chemotherapy for anal cancer. EORTC Radiotherapy and Gastrointestinal Cooperative Groups.
Lancet 1997;349(9046):205-6.
1997: Bartelink H; Rubens R D; van der Schueren E; Sylvester R
Hormonal therapy prolongs survival in irradiated locally advanced breast cancer: a European Organization for Research and Treatment of Cancer Randomized Phase III Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(1):207-15.
1996: Lara P C; Russell N S; Smolders I J; Bartelink H; Begg A C; Coco-Martin J M
Radiation-induced differentiation of human skin fibroblasts: relationship with cell survival and collagen production.
International journal of radiation biology 1996;70(6):683-92.
1996: Roeleveld T A; Horenblas S; Moonen L M; te Velde A; Meinhardt W; Bartelink H
[Internal radiotherapy in prostatic carcinoma; disappointing long-term results of retropubic Iodine-125 implantation]
Nederlands tijdschrift voor geneeskunde 1996;140(37):1855-9.
1996: Schuster-Uitterhoeve A L; van de Vaart P J; Schaake-Koning C C; Benraadt J; Koolen M G; González González D; Bartelink H
Feasibility of escalating daily doses of cisplatin in combination with accelerated radiotherapy in non-small cell lung cancer.
European journal of cancer (Oxford, England : 1990) 1996;32A(8):1314-9.
1996: Moonen L M; Horenblas S; Pos F; Schaefer B S; Meinhardt W; Bartelink H
[Good results of bladder-preserving treatment in poorly differentiated and invasive bladder carcinoma using interstitial Iridium-192 radiotherapy]
Nederlands tijdschrift voor geneeskunde 1996;140(27):1406-10.
1996: Coco-Martin J M; Ottenheim C P; Bartelink H; Begg A C
Lethality of radiation-induced chromosome aberrations in human tumour cell lines with different radiosensitivities.
International journal of radiation biology 1996;69(3):337-44.
1996: Bernier J; Horiot J C; Bartelink H; Johansson K A; Cionini L; Gonzalèz Gonzalèz D; Hamers H; van den Bogaert W
Profile of radiotherapy departments contributing to the Cooperative Group of Radiotherapy of the European Organization for Research and Treatment of Cancer.
International journal of radiation oncology, biology, physics 1996;34(4):953-60.
1996: Borger J; Bartelink H
Does the sequence of radiotherapy and chemotherapy in breast-conserving therapy influence outcome?
The cancer journal from Scientific American 1996;2(1):19-20.
1995: van Tienhoven G; Borger J H; Passchier D H; Hart A A; Rutgers E J; van Dongen J A; Bartelink H
The prognostic significance of the axillary apex biopsy in clinically operable breast cancer.
European journal of cancer (Oxford, England : 1990) 1995;31A(12):1965-8.
1995: Russell N S; Arlett C F; Bartelink H; Begg A C
Use of fluorescence in situ hybridization to determine the relationship between chromosome aberrations and cell survival in eight human fibroblast strains.
International journal of radiation biology 1995;68(2):185-96.
1995: Bolla M; Bartelink H; Garavaglia G; Gonzalez D; Horiot J C; Johansson K A; van Tienhoven G; Vantongelen K; van Glabbeke M
EORTC guidelines for writing protocols for clinical trials of radiotherapy.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 1995;36(1):1-8.
1995: Aleman B M; Bartelink H; Gunderson L L
The current role of radiotherapy in colorectal cancer.
European journal of cancer (Oxford, England : 1990) 1995;31A(7-8):1333-9.
1995: Pavy J J; Denekamp J; Letschert J; Littbrand B; Mornex F; Bernier J; Gonzales-Gonzales D; Horiot J C; Bolla M; Bartelink H
EORTC Late Effects Working Group. Late effects toxicity scoring: the SOMA scale.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 1995;35(1):11-5.
1995: Pavy J J; Denekamp J; Letschert J; Littbrand B; Mornex F; Bernier J; Gonzales-Gonzales D; Horiot J C; Bolla M; Bartelink H
EORTC Late Effects Working Group. Late Effects toxicity scoring: the SOMA scale.
International journal of radiation oncology, biology, physics 1995;31(5):1043-7.
1995: Bosset J F; Pelissier E; Mantion G; Pavy J J; Horiot J C; Hamers H P; Bartelink H
In response to McLean and Duncan.
International journal of radiation oncology, biology, physics 1995;31(4):1024-5.
1995: Kemperman H; Borger J; Hart A; Peterse H; Bartelink H; van Dongen J
Prognostic factors for survival after breast conserving therapy for stage I and II breast cancer. The role of local recurrence.
European journal of cancer (Oxford, England : 1990) 1995;31A(5):690-8.
1994: Borger J H; Kemperman H; Smitt H S; Hart A; van Dongen J; Lebesque J; Bartelink H
Dose and volume effects on fibrosis after breast conservation therapy.
International journal of radiation oncology, biology, physics 1994;30(5):1073-81.
1994: Smeets M F; Mooren E H; Abdel-Wahab A H; Bartelink H; Begg A C
Differential repair of radiation-induced DNA damage in cells of human squamous cell carcinoma and the effect of caffeine and cysteamine on induction and repair of DNA double-strand breaks.
Radiation research 1994;140(2):153-60.
1994: Moonen L; Bartelink H
Fractionation in radiotherapy.
Cancer treatment reviews 1994;20(4):365-78.
1994: Rutgers E J; Peterse J L; Bartelink H; van Dongen J A
Surgical treatment and deciding definitive management policy in a premenopausal patient with early breast cancer.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 1994;20(5):607-9; discussion 609-10.
1994: Moonen L M; Horenblas S; van der Voet J C; Nuyten M J; Bartelink H
Bladder conservation in selected T1G3 and muscle-invasive T2-T3a bladder carcinoma using combination therapy of surgery and iridium-192 implantation.
British journal of urology 1994;74(3):322-7.
1994: Coco-Martin J M; Smeets M F; Poggensee M; Mooren E; Hofland I; van den Brug M; Ottenheim C; Bartelink H; Begg A C
Use of fluorescence in situ hybridization to measure chromosome aberrations as a predictor of radiosensitivity in human tumour cells.
International journal of radiation biology 1994;66(3):297-307.
1994: Letschert J G; Lebesque J V; Aleman B M; Bosset J F; Horiot J C; Bartelink H; Cionini L; Hamers J P; Leer J W; van Glabbeke M
The volume effect in radiation-related late small bowel complications: results of a clinical study of the EORTC Radiotherapy Cooperative Group in patients treated for rectal carcinoma.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 1994;32(2):116-23.
1994: Bel A; Bartelink H; Vijlbrief R E; Lebesque J V
Transfer errors of planning CT to simulator: a possible source of setup inaccuracies?
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 1994;31(2):176-80.
1994: Begg A C; Deurloo M J; Kop W; Bartelink H
Improvement of combined modality therapy with cisplatin and radiation using intratumoral drug administration in murine tumors.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 1994;31(2):129-37.
1994: Bosset J F; Pelissier E P; Maniion G; Pavy J J; Horiot J C; Hamers H P; Bartelink H
Plea for a preoperative adjuvant approach in the management of rectal cancer.
International journal of radiation oncology, biology, physics 1994;29(1):205-8; discussion 215-6.
1994: Borger J; Kemperman H; Hart A; Peterse H; van Dongen J; Bartelink H
Risk factors in breast-conservation therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(4):653-60.
1994: Ptaszynski A; Van den Bogaert W; Van Glabbeke M; Pierart M; Bartelink H; Horiot J C; Fourquet A; Struikmans H; Hamers H; Müller R P
Patient population analysis in EORTC trial 22881/10882 on the role of a booster dose in breast-conserving therapy.
European journal of cancer (Oxford, England : 1990) 1994;30A(14):2073-81.
1993: Bel A; van Herk M; Bartelink H; Lebesque J V
A verification procedure to improve patient set-up accuracy using portal images.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 1993;29(2):253-60.
1993: Gregoire V; Begg A C; Huiskamp R; Verrijk R; Bartelink H
Selectivity of boron carriers for boron neutron capture therapy: pharmacological studies with borocaptate sodium, L-boronophenylalanine and boric acid in murine tumors.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 1993;27(1):46-54.
1993: el-Gayed A A; Bel A; Vijlbrief R; Bartelink H; Lebesque J V
Time trend of patient setup deviations during pelvic irradiation using electronic portal imaging.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 1993;26(2):162-71.
1993: Zoetmulder F A; Borger J H; Rutgers E J; Bergman R; Peterse J; Bartelink H
Breast conserving therapy in patients with relatively large (T2, T3) breast cancers by preoperative irradiation and myocutaneous LD flap reconstruction. A new technique in breast conservation.
European journal of cancer (Oxford, England : 1990) 1993;29A(7):957-61.
1992: Borger J H; van Tienhoven G; Passchier D H; Hart A A; van Dongen J A; Rutgers E J; Bartelink H
Primary radiotherapy of breast cancer: treatment results in locally advanced breast cancer and in operable patients selected by positive axillary apex biopsy.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 1992;25(1):1-11.
1992: Russell N S; Bartelink H
Optimized radiotherapy for head and neck cancer.
Current opinion in oncology 1992;4(3):491-8.
1992: van Dongen J A; Bartelink H; Fentiman I S; Lerut T; Mignolet F; Olthuis G; van der Schueren E; Sylvester R; Winter J; van Zijl K
Randomized clinical trial to assess the value of breast-conserving therapy in stage I and II breast cancer, EORTC 10801 trial.
Journal of the National Cancer Institute. Monographs 1992;(11):15-8.
1992: van Dongen J A; Bartelink H; Fentiman I S; Lerut T; Mignolet F; Olthuis G; van der Schueren E; Sylvester R; Tong D; Winter J
Factors influencing local relapse and survival and results of salvage treatment after breast-conserving therapy in operable breast cancer: EORTC trial 10801, breast conservation compared with mastectomy in TNM stage I and II breast cancer.
European journal of cancer (Oxford, England : 1990) 1992;28A(4-5):801-5.
1991: Bartelink H; Garavaglia G; Johansson K A; Mijnheer B J; Van den Bogaert W; van Tienhoven G; Yarnold J
Quality assurance in conservative treatment of early breast cancer. Report on a consensus meeting of the EORTC Radiotherapy and Breast Cancer Cooperative Groups and the EUSOMA (European Society of Mastology).
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 1991;22(4):323-6.
1991: van Tienhoven G; van Bree N A; Mijnheer B J; Bartelink H
Quality assurance of the EORTC trial 22881/10882: "assessment of the role of the booster dose in breast conserving therapy": the Dummy Run. EORTC Radiotherapy Cooperative Group.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 1991;22(4):290-8.
1991: Letschert J G; González González D; Oskam J; Koornneef L; van Dijk J D; Boukes R; Bras J; van Heerde P; Bartelink H
Results of radiotherapy in patients with stage I orbital non-Hodgkin's lymphoma.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 1991;22(1):36-44.
1991: Stewart F A; Bartelink H; van der Voet G B; de Wolff F A
Renal damage in mice after sequential cisplatin and irradiation: the influence of prior irradiation on platinum elimination.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 1991;21(4):277-81.
1991: Bartelink H; Keus R B
Progress in radiotherapy by treatment tailoring in head and neck cancer.
Current opinion in oncology 1991;3(3):523-8.
1991: Deurloo M J; Kop W; van Tellingen O; Bartelink H; Begg A C
Intratumoural administration of cisplatin in slow-release devices: II. Pharmacokinetics and intratumoural distribution.
Cancer chemotherapy and pharmacology 1991;27(5):347-53.
1991: Schaake-Koning C; Kirkpatrick A; Kröger R; van Zandwijk N; Bartelink H
The need for immediate monitoring of treatment parameters and uniform assessment of patient data in clinical trials. A quality control study of the EORTC Radiotherapy and Lung Cancer Cooperative Groups.
European journal of cancer (Oxford, England : 1990) 1991;27(5):615-9.
1990: Begg A C; Hofland I; Moonen L; Bartelink H; Schraub S; Bontemps P; Le Fur R; Van Den Bogaert W; Caspers R; Van Glabbeke M
The predictive value of cell kinetic measurements in a European trial of accelerated fractionation in advanced head and neck tumors: an interim report.
International journal of radiation oncology, biology, physics 1990;19(6):1449-53.
1990: Schaake-Koning C; Maat B; van Houtte P; van den Bogaert W; Dalesio O; Kirkpatrick A; Bartelink H
Radiotherapy combined with low-dose cis-diammine dichloroplatinum (II) (CDDP) in inoperable nonmetastatic non-small cell lung cancer (NSCLC): a randomized three arm phase II study of the EORTC Lung Cancer and Radiotherapy Cooperative Groups.
International journal of radiation oncology, biology, physics 1990;19(4):967-72.
1990: Letschert J G; Lebesque J V; de Boer R W; Hart A A; Bartelink H
Dose-volume correlation in radiation-related late small-bowel complications: a clinical study.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 1990;18(4):307-20.
1990: Meertens H; van Herk M; Bijhold J; Bartelink H
First clinical experience with a newly developed electronic portal imaging device.
International journal of radiation oncology, biology, physics 1990;18(5):1173-81.
1990: Bartelink H; Jassem J
Early presentation of results in clinical trials: an ethical dilemma for medicine and science.
European journal of cancer (Oxford, England : 1990) 1990;26(4):419-20.
1990: Deurloo M J; Bohlken S; Kop W; Lerk C F; Hennink W; Bartelink H; Begg A C
Intratumoural administration of cisplatin in slow-release devices. I. Tumour response and toxicity.
Cancer chemotherapy and pharmacology 1990;27(2):135-40.
1989: Dewit L; Oussoren Y; Bartelink H; Thames H D
The effect of cis-diamminedichloroplatinum(II) on radiation damage in mouse rectum after fractionated irradiation.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 1989;16(2):121-8.
1989: Stewart F A; Oussoren Y; Bartelink H
The influence of cisplatin on the response of mouse kidneys to multifraction irradiation.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 1989;15(1):93-102.
1989: Begg A C; Bohlken S; Bartelink H
The effect of cisplatin on the repair of radiation damage in RIF1 mouse tumours in vivo.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 1989;15(1):79-91.
1988: Meertens H; Bartelink H; Minderhoud T
First clinical experience with a remote afterloading system for low dose rate interstitial breast implants.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 1988;11(4):387-93.
1988: Begg A C; Moonen L; Hofland I; Dessing M; Bartelink H
Human tumour cell kinetics using a monoclonal antibody against iododeoxyuridine: intratumour sampling variations.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 1988;11(4):337-47.
1988: Aaronson N K; Bartelink H; van Dongen J A; van Dam F S
Evaluation of breast conserving therapy: clinical, methodological and psychosocial perspectives.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 1988;14(2):133-40.
1988: Bartelink H; Borger J H; van Dongen J A; Peterse J L
The impact of tumor size and histology on local control after breast-conserving therapy.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 1988;11(4):297-303.
1988: Peterse J L; van Dongen J A; Bartelink H
Recurrence of breast carcinoma after breast conserving treatment.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 1988;14(2):123-6.
1988: Stewart F A; Luts A; Oussoren Y; Begg A C; Dewit L; Bartelink H
Renal damage in mice after treatment with cisplatin and x-rays: comparison of fractionated and single-dose studies.
NCI monographs : a publication of the National Cancer Institute 1988;(6):23-7.
1988: Begg A C; Bartelink H; Stewart F A; Brown D M; Luck E E
Improvement of differential toxicity between tumor and normal tissues using intratumoral injection with or without a slow-drug-release matrix system.
NCI monographs : a publication of the National Cancer Institute 1988;(6):133-6.
1988: Bartelink H
Combined modality treatment for primary tumor.
NCI monographs : a publication of the National Cancer Institute 1988;(6):247-51.
1987: Stewart F A; Oussoren Y; Luts A; Begg A C; Dewit L; Lebesque J; Bartelink H
Repair of sublethal radiation injury after multiple small doses in mouse kidney: an estimate of flexure dose.
International journal of radiation oncology, biology, physics 1987;13(5):765-72.
1987: Dewit L; Oussoren Y; Bartelink H
Early and late damage in the mouse rectum after irradiation and cis-diamminedichloroplatinum(II).
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 1987;8(1):57-69.
1986: Dewit L; Oussoren Y; Bartelink H
The effects of cis-diamminedichloroplatinum (II) and radiation on the proliferation kinetics of mouse duodenal crypt cells and on a partially synchronized crypt cell population.
International journal of radiation oncology, biology, physics 1986;12(11):1977-85.
1985: Dewit L; Oussoren Y; Bartelink H
Dose and time effects of cis-diamminedichloroplatinum(II) and radiation on mouse duodenal crypts.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 1985;4(4):363-71.
1985: Dewit L; Oussoren Y; Bartelink H; Stewart F A
Differences in the acute intestinal syndrome after partial and total abdominal irradiation in mice.
International journal of radiation biology and related studies in physics, chemistry, and medicine 1985;48(5):745-52.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Harry Bartelink

Research Profile (preview)

Disorders

Concepts & Ideas

Procedures

Chemicals & Drugs

Living Beings

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Harry Bartelink (preview)

All Publications